EURECA: Urinary and Sexual Dysfunctions Evaluation After Rectal Resection

Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Other)
Overall Status
Recruiting
CT.gov ID
NCT04404673
Collaborator
(none)
1,172
1
48
24.4

Study Details

Study Description

Brief Summary

Advances in the treatment of rectal cancer over the past two decades have improved survival and significantly reduced surgery-related morbidity. As a result, post-treatment quality of life (QoL) issues have become increasingly important. Urinary and sexual functions can be significantly altered after rectal resection, mainly due to the iatrogenic lesions of the pelvic autonomous lexus. Of note, their incidence is reported up to 70% and 30%, respectively. Despite the importance of this topic, most of the studies present in the literature are difficult to interpret for a variety of reasons. Firstly, both sexual and urinary dysfunctions lack a standardized definition. Secondly, the absence of baseline data, missing data, small sample sizes, and heterogeneity in the use of validated and nonvalidated instruments are the main limitation in drawing conclusive results. As additional factor, no clear evidence is present in the literature regarding the best approach to be used in order to preserve as much as possible both the sexual and urinary functionalities and to guarantee, at the same time, an adequate and oncologically correct rectal resection. Moreover, no data are currently present regarding the impact of pre-operative chemo-radiotherapy on the urinary and sexual functionalities. The main objective of the investigator's prospective study will be to define in a subjective manner which technique (open, laparoscopic, robot-assisted and Ta-TME) will guarantee the best urinary and sexual outcomes after rectal resection (with or without pre-operative chemo-radiotherapy) for the treatment of rectal carcinomas.

Thus, the primary endpoint will the post-operative evaluation at 1, 6 months and 1 year of the urinary and sexual functions by means of specific questionnaires.

Secondary endpoints will be:
  • to investigate which technique (open, robotic, laparoscopic and trans-anal total mesorectal excision (TaTME)) more favorably correlate with urinary and sexual functions after radiochemotherapy (NAD+);

  • the comparison of both the urinary and sexual dysfunction incidence on the base of the distance of the rectal tumor from the anal verge and the evaluation of the best approach to be used (open, laparoscopic, TaTME or robot-assisted) in relation to the tumor height;

  • the short- (postoperative morbidity and histopathological data) and long-term (overall and disease-free survival) outcomes comparison among the open, laparoscopic, TaTME and robotic rectal resection.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Evaluation of urinary and sexual dysfunction after rectal resection

Study Design

Study Type:
Observational
Anticipated Enrollment :
1172 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Multicenter Prospective Evaluation of Urinary and Sexual Dysfunctions After Rectal Cancer Resection
Actual Study Start Date :
Feb 21, 2020
Anticipated Primary Completion Date :
Feb 20, 2024
Anticipated Study Completion Date :
Feb 20, 2024

Arms and Interventions

Arm Intervention/Treatment
Open rectal resection

Procedure: Evaluation of urinary and sexual dysfunction after rectal resection
Comparison among the 4 different surgical approaches for urinary and sexual function

Laparoscopic rectal resection

Procedure: Evaluation of urinary and sexual dysfunction after rectal resection
Comparison among the 4 different surgical approaches for urinary and sexual function

Robotic rectal resection

Procedure: Evaluation of urinary and sexual dysfunction after rectal resection
Comparison among the 4 different surgical approaches for urinary and sexual function

Trans-anal TME (Ta-TME)

Procedure: Evaluation of urinary and sexual dysfunction after rectal resection
Comparison among the 4 different surgical approaches for urinary and sexual function

Outcome Measures

Primary Outcome Measures

  1. Urinary and sexual outcomes after rectal resection [At 1 month after surgery]

    Which technique (open, laparoscopic, robot-assisted and Ta-TME) will guarantee the best urinary and sexual outcomes after rectal resection (with or without pre-operative chemo-radiotherapy) for the treatment of rectal carcinomas

  2. Urinary and sexual outcomes after rectal resection [At 6 months after surgery]

    Which technique (open, laparoscopic, robot-assisted and Ta-TME) will guarantee the best urinary and sexual outcomes after rectal resection (with or without pre-operative chemo-radiotherapy) for the treatment of rectal carcinomas

  3. Urinary and sexual outcomes after rectal resection [At 12 months after surgery]

    Which technique (open, laparoscopic, robot-assisted and Ta-TME) will guarantee the best urinary and sexual outcomes after rectal resection (with or without pre-operative chemo-radiotherapy) for the treatment of rectal carcinomas

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • All patients with a histopathological proven diagnosis of rectal carcinoma undergoing curative surgical resection
Exclusion Criteria:
  • Patients aged < 18 years

  • Inability to give informed consent

  • Emergent surgeries

  • Previous prostatic and/or colorectal surgery for benign or malignant diseases

  • Preoperative sexual disorders (Female Sexual Function Index, FSFI ≤ 26.55 ; International Index Erectile Function , IIEF < 16)

  • International Consultation on Incontinence Questionnaire > 5

  • Clinically evident Benign Prostatic Hypertrophy (BPH) (International Prostatic Symptoms Score, IPSS > 20)

  • Preoperative diagnosis of fecal and/or urinary incontinence.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Fondazione Policlinico Universitario Agostino Gemelli IRCCS di Roma Roma Lazio Italy 00168

Sponsors and Collaborators

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
ClinicalTrials.gov Identifier:
NCT04404673
Other Study ID Numbers:
  • 2987
First Posted:
May 27, 2020
Last Update Posted:
May 27, 2020
Last Verified:
May 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 27, 2020